| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
| Targets |
α-Demethylnaproxen is the major metabolite of nabumetone, which is a COX-2 inhibitor. As a metabolite, it contributes to the anti-inflammatory activity of the parent drug. It is used as a marker for nabumetone exposure and metabolism.
|
|---|---|
| ln Vitro |
In vitro, α-demethylnaproxen is the major metabolite of nabumetone. It is used as a reference standard for the quantification of nabumetone metabolism. Its anti-inflammatory activity is attributed to COX-2 inhibition, similar to the parent drug.
|
| ln Vivo |
In vivo, α-demethylnaproxen is the major metabolite of nabumetone. Nabumetone is an orally active COX-2 inhibitor with anti-inflammatory activity. The metabolite contributes to the therapeutic effects of the parent drug and is used as a biomarker of nabumetone exposure.
|
| Enzyme Assay |
In vitro assays for α-demethylnaproxen typically involve its detection and quantification as a metabolite of nabumetone. The compound is extracted from biological samples and analyzed by HPLC or LC-MS. It is used as a reference standard for pharmacokinetic studies. COX-2 inhibition assays may be performed to assess its activity.
|
| Cell Assay |
For in vitro cell assays, cells are cultured and treated with nabumetone or α-demethylnaproxen. The compound's anti-inflammatory activity is assessed by measuring prostaglandin production or cytokine levels. Cell viability is assessed by MTT assay. The compound's effects on COX-2 activity are evaluated in cell-based assays.
|
| Animal Protocol |
For in vivo animal studies, α-demethylnaproxen is studied as the major metabolite of nabumetone. Animals are administered nabumetone, and blood and tissue samples are collected. The compound is quantified by LC-MS. Its pharmacokinetic profile and contribution to the anti-inflammatory effects of nabumetone are assessed.
|
| ADME/Pharmacokinetics |
α-Demethylnaproxen (MW 216.23) has the molecular formula C₁₃H₁₂O₃. It is also known as (6-methoxynaphthalen-2-yl)acetic acid. The compound is stable under recommended storage conditions. It is soluble in organic solvents and is used as a reference standard for analytical methods.
|
| Toxicity/Toxicokinetics |
The compound is for research use only. No specific toxicity data are available. As a metabolite of nabumetone, its toxicity profile is expected to be related to the parent drug. Standard laboratory safety precautions should be followed when handling this compound.
|
| References |
[1]. Mikami E, et al. Simultaneous analysis of naproxen, nabumetone and its major metabolite 6-methoxy-2-naphthylacetic acid in pharmaceuticals and human urine by high-performance liquid chromatography. J Pharm Biomed Anal. 2000 Oct;23(5):917-25.
[2]. Vural F, et al. Cyclo-oxygenase 2 inhibitor, nabumetone, inhibits proliferation in chronic myeloid leukemia cell lines. Leuk Lymphoma. 2005 May;46(5):753-6. |
| Additional Infomation |
(6-Methoxy-2-naphthyl)acetic acid is a monocarboxylic acid composed of 2-naphthylacetic acid with a methoxy substituent at the 6-position. It is the active metabolite of the prodrug nabumetone. It functions as an EC 1.14.99.1 (prostaglandin intraperoxide synthase) inhibitor, a drug metabolite, and an exogenous metabolite. It is a monocarboxylic acid belonging to the methoxynaphthalene class of compounds. Its function is related to that of 2-naphthylacetic acid.
α-Demethylnaproxen (CAS# 23981-47-7) is the major metabolite of the COX-2 inhibitor nabumetone. It has not been approved as a therapeutic agent. The compound is used as a reference standard in pharmacokinetic studies and as a marker for nabumetone exposure. It is also known as Naproxen Imp. I (EP) and 6-methoxy-2-naphthaleneacetic acid. |
| Molecular Formula |
C13H12O3
|
|---|---|
| Molecular Weight |
216.23
|
| Exact Mass |
216.078
|
| CAS # |
23981-47-7
|
| Related CAS # |
α-Demethylnaproxen; 23981-47-7
|
| PubChem CID |
32176
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
408.8±20.0 °C at 760 mmHg
|
| Melting Point |
171-173ºC
|
| Flash Point |
160.7±15.3 °C
|
| Vapour Pressure |
0.0±1.0 mmHg at 25°C
|
| Index of Refraction |
1.625
|
| LogP |
2.65
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
16
|
| Complexity |
252
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O(C([H])([H])[H])C1C([H])=C([H])C2C([H])=C(C([H])([H])C(=O)O[H])C([H])=C([H])C=2C=1[H]
|
| InChi Key |
PHJFLPMVEFKEPL-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C13H12O3/c1-16-12-5-4-10-6-9(7-13(14)15)2-3-11(10)8-12/h2-6,8H,7H2,1H3,(H,14,15)
|
| Chemical Name |
2-(6-methoxynaphthalen-2-yl)acetic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~5 mg/mL (~23.1 mM; with ultrasonication and warming by heating to 60°C)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 0.5 mg/mL (2.31 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (5.0 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 0.5 mg/mL (2.31 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (5.0 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 0.5 mg/mL (2.31 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (5.0 mg/mL) to 900 μL of corn oil and mix well. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.6247 mL | 23.1235 mL | 46.2471 mL | |
| 5 mM | 0.9249 mL | 4.6247 mL | 9.2494 mL | |
| 10 mM | 0.4625 mL | 2.3124 mL | 4.6247 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
